Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors

Urol Int. 2011;87(2):134-7. doi: 10.1159/000330246. Epub 2011 Aug 24.

Abstract

Objective: To investigate the diagnostic value of the nuclear matrix protein 22 (NMP22) test in comparison to urine cytology for the detection of upper tract urothelial carcinoma.

Patients and methods: Patients with transitional cell carcinoma of the upper urinary tract (n = 34) and patients with renal calculosis (n = 25) were included in this study. Voided urine samples and separated catheter urine specimens were assayed for NMP22 and cytological examination.

Results: The sensitivity of the NMP22 test in separated and voided urine was 73.2 and 70.5%, respectively, compared to 64.7 and 58.8% of urine cytology. The specificity of the NMP22 test in separated and voided urine was 88 and 92%, respectively, compared to 96 and 96% of urine cytology. The combination of separated and voided urine is the best method because the sensitivity is 79.41% and specificity 88%. There is a high agreement of the NMP22 test in voided and separated urine (kappa = 0.795, p < 0.01), indicating that the voided urine is adequate for diagnosis.

Conclusions: The NMP22 test has higher sensitivity but lower specificity than cytology. The combination of these two tests could be a very useful diagnostic method for detection of upper urothelial tumors.

MeSH terms

  • Adult
  • Carcinoma / metabolism*
  • Carcinoma / urine*
  • Case-Control Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nuclear Proteins / metabolism*
  • Nuclear Proteins / urine*
  • Predictive Value of Tests
  • Risk
  • Sensitivity and Specificity
  • Urinary Bladder Neoplasms / metabolism*
  • Urinary Bladder Neoplasms / urine*
  • Urology / methods
  • Urothelium / pathology*

Substances

  • Nuclear Proteins
  • nuclear matrix protein 22